COMP <GO>
LEXX vs MTVA // EV/EBITDA & P/E VALUATION
Lexaria Bioscience Corp. (NASDAQ) VS. MetaVia Inc. (NASDAQ) • 15-METRIC TALLY: LEXX 3
— MTVA 0
■ METRIC PARITY
LAST: $3.77 (+14.24%) • MKT CAP: $7.9M
valuation
—
LAST: $1.19 (+4.39%) • MKT CAP: $7.8M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LEXX VS. MTVA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | LEXX | MTVA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 52.00% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 2/9 | +2.00 | LEXX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.6 | 32.2 | +16.48 | LEXX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.9M | $7.8M | $101.8K | LEXX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | LEXX REV | MTVA REV | LEXX GROSS % | MTVA GROSS % | LEXX FCF | MTVA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $705.9K | $0 | 98.0% | — | -$10.5M | -$15.7M |
| FY 2024 | $464.3K | $0 | 98.0% | — | -$5.0M | -$24.7M |
| FY 2023 | $226.2K | $0 | — | — | -$5.9M | -$10.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LEXX // BETA —
MTVA // BETA —